Literature DB >> 22258344

Unicentric Castleman disease relapsed after rituximab-CHOP chemotherapy or radiation therapy in an adolescent.

Hee Jo Baek1, Hoon Kook, Dong Kyun Han, Myung-Geun Shin, Hyoung Seok Kim, Tai Ju Hwang.   

Abstract

Castleman disease (CD), an atypical lymphoproliferative disorder of unknown etiology, is rare. Unicentric CD can be cured after resection of the involved lymph nodes. However, rarely, patients with the unicentric-plasma cell variant may require additional therapy after resection for persistent systemic symptoms. The clinical course of such patients has not been well characterized. We report the case with relapsed unicentric-plasma cell variant CD who was eventually treated with complete surgical resection. This patient had no response to combination chemotherapy with rituximab after incomplete resection and no response to radiation after relapse.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22258344     DOI: 10.1097/MPH.0b013e3182352dc7

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  4 in total

1.  Castleman disease mimicked pancreatic carcinoma: report of two cases.

Authors:  Hua Guo; Yan Shen; Wei-Lin Wang; Min Zhang; Hong Li; Ying-Sheng Wu; Sheng Yan; Xiao Xu; Jian Wu; Shu-Sen Zheng
Journal:  World J Surg Oncol       Date:  2012-07-23       Impact factor: 2.754

2.  Mesenteric Castleman's disease mimicking neuroendocrine tumour.

Authors:  Ricky H Bhogal; Andrew Wotherspoon; Aamir K Khan
Journal:  Int J Surg Case Rep       Date:  2019-09-18

3.  Rare Forms of Castleman Disease Mimicking Malignancy: Mesenteric and Pancreatic Involvement.

Authors:  Mustafa Ozsoy; Zehra Ozsoy; Suleyman Sahin; Yuksel Arıkan
Journal:  Cureus       Date:  2018-03-12

Review 4.  Unicentric Castleman disease presenting as a retroperitoneal peripancreatic mass: A report of two cases and review of literature.

Authors:  Jia-Lin Cheng; Jing Cui; Yi Wang; Zong-Zhen Xu; Feng Liu; Shu-Bin Liang; Hu Tian
Journal:  World J Gastroenterol       Date:  2018-09-14       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.